Beam Therapeutics/$BEAM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Beam Therapeutics
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Ticker
$BEAM
Sector
Primary listing
Employees
509
Headquarters
Website
BEAM Metrics
BasicAdvanced
$2.2B
-
-$4.49
2.23
-
Price and volume
Market cap
$2.2B
Beta
2.23
52-week high
$35.25
52-week low
$13.53
Average daily volume
2.8M
Financial strength
Current ratio
6.75
Quick ratio
6.606
Long term debt to equity
13.551
Total debt to equity
14.788
Profitability
EBITDA (TTM)
-423.994
Gross margin (TTM)
-500.07%
Net profit margin (TTM)
-661.31%
Operating margin (TTM)
-739.94%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-21.02%
Return on equity (TTM)
-41.94%
Valuation
Price to revenue (TTM)
33.084
Price to book
2.1
Price to tangible book (TTM)
2.1
Price to free cash flow (TTM)
-5.608
Free cash flow yield (TTM)
-17.83%
Free cash flow per share (TTM)
-4.003
Growth
Revenue change (TTM)
-82.90%
Earnings per share change (TTM)
154.00%
3-year revenue growth (CAGR)
-7.81%
3-year earnings per share growth (CAGR)
9.46%
What the Analysts think about BEAM
Analyst ratings (Buy, Hold, Sell) for Beam Therapeutics stock.
Bulls say / Bears say
Beam closed Q2 2025 with $1.2 billion in cash, extending its funding runway into 2028 and ensuring support for its main clinical programs. (Beam Therapeutics)
First data from the BEAM-302 Phase 1/2 trial showed durable, dose-related increases in functional alpha-1 antitrypsin and reductions in mutant Z-AAT, with no serious adverse events. This supports proof of concept for in vivo base editing. (Beam Therapeutics)
Updated BEAM-101 results from the BEACON Phase 1/2 trial found all 17 treated patients showed greater than 60% fetal hemoglobin induction and sustained resolution of anemia, with no vaso-occlusive crises after engraftment. (Beam Therapeutics)
R&D expenses rose to $101.8 million in Q2 2025 from $87.0 million a year earlier, and net loss widened to $102.3 million. This highlights a high cash burn prior to potential approval and commercialization. (Beam Therapeutics)
All of Beam's lead programs are still in early Phase 1/2 trials, with pivotal data not expected until late 2025 or 2026. This leaves the company exposed to development and clinical risk. (Beam Therapeutics)
Beam’s shares have lagged behind other gene-editing stocks, down about 29% year to date amid market volatility and funding concerns. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
BEAM Financial Performance
Revenues and expenses
BEAM Earnings Performance
Company profitability
BEAM News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Beam Therapeutics stock?
Beam Therapeutics (BEAM) has a market cap of $2.2B as of September 18, 2025.
What is the P/E ratio for Beam Therapeutics stock?
The price to earnings (P/E) ratio for Beam Therapeutics (BEAM) stock is 0 as of September 18, 2025.
Does Beam Therapeutics stock pay dividends?
No, Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Beam Therapeutics dividend payment date?
Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders.
What is the beta indicator for Beam Therapeutics?
Beam Therapeutics (BEAM) has a beta rating of 2.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.